Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced on October 13, 2026, the appointment of Jeffrey Farrow to its Board of Directors, effective immediately. The appointment was made upon the recommendation of the Nominating and Corporate Governance Committee. The move expands the Company's Board of Directors from seven to eight members, with Mr. Farrow filling a newly created Class III seat. His initial term is set to expire at the Company's 2028 annual meeting of stockholders.
Mr. Farrow has been appointed as a member of the Audit Committee. The Board has determined that he is an independent director in accordance with the listing requirements of the Nasdaq Capital Market. He has entered into the Company’s standard form of indemnification agreement.
Jeffrey Farrow, age 65, currently serves as the Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a commercial-stage biopharmaceutical company focused on eye care. He has held this role since April 2023. Additionally, he serves as a director of Clover Biopharmaceuticals, Ltd., a company listed on the Hong Kong Stock Exchange, and as a director, chairperson of the audit committee, and member of the nominating and corporate governance committee of Achieve Life Sciences, Inc. (Nasdaq: ACHV).
Mr. Farrow’s prior experience includes serving as Chief Financial Officer of Global Blood Therapeutics, Inc. from April 2016 until December 2022, when the company was acquired by Pfizer Inc. He also previously served as CFO of ZS Pharma, Inc., which was acquired by AstraZeneca in December 2015, and as CFO of Hyperion Therapeutics, Inc., which was acquired by Horizon Therapeutics in May 2015. Earlier in his career, he held finance leadership roles at Evotec AG and Renovis, Inc., and spent seven years in the audit practice of KPMG LLP. Mr. Farrow holds a B.A. in business administration with a concentration in corporate finance from California State University, Fullerton, and is a certified public accountant (inactive).
Regarding the appointment, David J. Mazzo, PhD, Chief Executive Officer of Lisata, stated, “Jeff has helped take multiple companies from the clinic to approval and commercial launch, and he has led several of them through successful strategic outcomes. As we advance our Phase 2b programs in severe hypertriglyceridemia and acromegaly, his financial discipline and public-company experience will be a tremendous asset to our Board.”
